- Home
- AUDC vs ESPR Comparison
AUDC vs ESPR Comparison
Compare AUDC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- ESPR
- Stock Information
- Founded
- AUDC 1992
- ESPR 2008
- Country
- AUDC Israel
- ESPR United States
- Employees
- AUDC N/A
- ESPR N/A
- Industry
- AUDC Telecommunications Equipment
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- AUDC Utilities
- ESPR Health Care
- Exchange
- AUDC Nasdaq
- ESPR Nasdaq
- Market Cap
- AUDC 279.1M
- ESPR 305.0M
- IPO Year
- AUDC 1999
- ESPR 2013
- Fundamental
- Price
- AUDC $8.44
- ESPR $0.89
- Analyst Decision
- AUDC Buy
- ESPR Buy
- Analyst Count
- AUDC 3
- ESPR 7
- Target Price
- AUDC $11.67
- ESPR $5.93
- AVG Volume (30 Days)
- AUDC 109.7K
- ESPR 5.7M
- Earning Date
- AUDC 05-06-2025
- ESPR 05-06-2025
- Dividend Yield
- AUDC 2.13%
- ESPR N/A
- EPS Growth
- AUDC 57.57
- ESPR N/A
- EPS
- AUDC 0.56
- ESPR N/A
- Revenue
- AUDC $242,474,000.00
- ESPR $259,574,000.00
- Revenue This Year
- AUDC $5.11
- ESPR $5.70
- Revenue Next Year
- AUDC $3.81
- ESPR N/A
- P/E Ratio
- AUDC $15.02
- ESPR N/A
- Revenue Growth
- AUDC N/A
- ESPR 12.99
- 52 Week Low
- AUDC $7.70
- ESPR $0.82
- 52 Week High
- AUDC $12.72
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- AUDC 35.54
- ESPR 36.95
- Support Level
- AUDC $8.01
- ESPR $0.93
- Resistance Level
- AUDC $9.84
- ESPR $1.11
- Average True Range (ATR)
- AUDC 0.31
- ESPR 0.10
- MACD
- AUDC -0.06
- ESPR 0.02
- Stochastic Oscillator
- AUDC 23.50
- ESPR 25.10
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.